Production system establishment and in vitro study of CD19/CD3ε bite antibody secreted from Pichia pastoris.

ABSTRACT: Blinatumomab is an anti-cancer Bispecific T-cell Engager (BiTE) antibody drug approved by the Food and Drug Administration (FDA) for treating acute lymphoblastic leukemia (ALL). It targets CD3ε, which is expressed on T cells and concomitantly targets CD19, an antigen specifically expressed in B-cell leukemia. Blinatumomab-bound T cells are activated to secrete perforin and granzyme, which induce cell death in B-cell leukemia. Blinatumomab is produced in the Chinese hamster ovary (CHO) cell expression system in consideration of post-translational modification (PTM) and immunogenicity. Although the characteristics of CHO cells are similar to those of other mammalian cells, it has low yield and high production cost. In this study, we developed the yeast species Pichia pastoris-produced BiTE a

SUBMITTER: Kim B 

PROVIDER: S-EPMC12575637 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature